早期内皮功能改善对高血压患者亚临床目标器官损伤的影响
Xiaodong Huang1,2, Xianwei Huang1,2, Mandong Pan1,2
1Department of Emergency, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
Scientific reports
|July 11, 2024
概括
在基本高血压 (EH) 患者中,内皮功能 (EEFI) 的早期改善显著降低了亚临床目标器官损伤 (STOD). 这种干预对于预防器官损伤至关重要,特别是在年轻的非吸烟者和控制胆固醇的人群中.
科学领域:
- 心血管医学 心血管医学
- 高血压研究 高血压研究
- 内皮功能研究 研究内皮功能研究.
背景情况:
- 内皮功能障碍是高血压中亚临床目标器官损伤 (STOD) 的公认标志物.
- 早期内皮功能改善 (EEFI) 对STOD预防的治疗影响仍然不清楚.
研究的目的:
- 评估EEFI是否可以降低基本高血压 (EH) 患者的STOD发病率.
主要方法:
- 在最初没有STOD的456名EH患者的回顾性队列分析.
- 通过手臂动脉流媒扩张 (FMD) 评估内皮功能;功能障碍定义为FMD ≤7.1%.
- 根据基线内皮质状况和三个月内改善而分类的患者; 随访时间中位数为25个月.
主要成果:
- 在177名患者中发生了STOD;初始内皮功能障碍患者的发病率更高.
- 卡普兰-梅尔分析显示,EEFI组的累积STOD发病率低于未改善组 (p <0.05).
- 多变量考克斯回归确定了EEFI作为STOD (p <0.05) 的独立保护因子,特别是在65岁以下的患者,非吸烟者和LDL-C ≤3.4 mmol/L的患者中.
结论:
- EEFI显著降低了EH患者中STOD的发生率.
- 针对内皮功能的早期干预对于预防STOD至关重要,特别是在确定高风险子组中.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
600
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
600
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502
Antihypertensive Drugs: Direct Renin Inhibitors
546
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
546


